

# Congcong Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2392118/publications.pdf>

Version: 2024-02-01

16  
papers

1,877  
citations

623734

14  
h-index

996975

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

2346  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity. , 2021, 9, e002980.		28
2	“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Scientific Reports, 2020, 10, 2141.	3.3	62
3	Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. BioDrugs, 2020, 34, 435-462.	4.6	24
4	CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 2683.	4.8	142
5	3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. EMBO Journal, 2019, 38, .	7.8	200
6	Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunology, Immunotherapy, 2018, 67, 25-38.	4.2	84
7	Evaluating the Delivery of Proteins to the Cytosol of Mammalian Cells. Methods in Molecular Biology, 2017, 1513, 201-208.	0.9	7
8	Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy, 2017, 19, 235-249.	0.7	142
9	Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Frontiers in Immunology, 2017, 8, 533.	4.8	232
10	ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Journal of the National Cancer Institute, 2016, 108, .	6.3	282
11	Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. OncoImmunology, 2016, 5, e1119354.	4.6	151
12	Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor. Molecular Therapy, 2015, 23, 330-338.	8.2	274
13	Delivery of antibodies to the cytosol. MAbs, 2014, 6, 943-956.	5.2	67
14	Suppression of p75 Neurotrophin Receptor Surface Expression with Intrabodies Influences Bcl-xL mRNA Expression and Neurite Outgrowth in PC12 Cells. PLoS ONE, 2012, 7, e30684.	2.5	25
15	Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Engineering, Design and Selection, 2007, 20, 491-496.	2.1	47
16	A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. Journal of Immunological Methods, 2007, 318, 113-124.	1.4	110